Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus
[Display omitted] Diabetes is a chronic medical condition, which is characterised by high blood sugar level. Exogenous insulin is commonly administered subcutaneously for the management of diabetes. However, daily injections of insulin could result in poor patient compliance and various side-effects...
Gespeichert in:
Veröffentlicht in: | International journal of pharmaceutics 2018-10, Vol.549 (1-2), p.201-217 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 217 |
---|---|
container_issue | 1-2 |
container_start_page | 201 |
container_title | International journal of pharmaceutics |
container_volume | 549 |
creator | Wong, Chun Y. Al-Salami, Hani Dass, Crispin R. |
description | [Display omitted]
Diabetes is a chronic medical condition, which is characterised by high blood sugar level. Exogenous insulin is commonly administered subcutaneously for the management of diabetes. However, daily injections of insulin could result in poor patient compliance and various side-effects. Although oral administration offers benefits, insulin is vulnerable to enzymatic degradation, chemical instability and poor gastrointestinal absorption. There is an absence of reviews on insulin-loaded liposomal drug carriers, despite that fact that liposomes have gained considerable attention recently for oral delivery of insulin. They demonstrate favourable characteristics, such as versatility, biocompatibility, protective effect against enzymatic degradation, and cell-specific targeting. In this review, we will explore the status quo for oral delivery of insulin-loaded liposomal formulations, followed by discussing the state of art of these vesicles. This review will provide a detailed overview on insulin-loaded conventional liposomes, and 7 types of current novel formulations. Lastly, the future direction for oral bioavailability enhancement and development of such nanoscale drug delivery systems will be discussed. Further optimisation in the drug entrapment efficiency and gastrointestinal absorption will be required to develop a clinically successful oral liposome-insulin formulation. |
doi_str_mv | 10.1016/j.ijpharm.2018.07.041 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2083724521</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517318305167</els_id><sourcerecordid>2083724521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-1987f9f5db0d5526423d1d73f24740e1380dcba15b1f570aab08d3ccd2ebf6703</originalsourceid><addsrcrecordid>eNqFkMFuFDEMhqOKim4XHgGUI5cZnMlkMntCqCpQqRJSBecokzglq8lkSTIr7duTaheunGzZv_3bHyHvGLQM2PBx3_r94ZdOoe2AjS3IFnp2RTZslLzhvRxekQ1wOTaCSX5DbnPeA8DQMf6a3HAAyTjsNiQ9ocGlUG2PejEYap6pX2hMeq7F4BefS9LFx1pztZPX2S_NHLVFS2d_iDmGKrVpfaYWZ3_EdKL5lAuGTF1M1Ho9YcFMA86zL2t-Q66dnjO-vcQt-fnl_sfdt-bx-9eHu8-PjeGDKA3bjdLtnLATWCG6oe-4ZVZy1_WyB2R8BGsmzcTEnJCg9QSj5cbYDic3SOBb8uG895Di7xVzUcFnU4_QC8Y1qw5GLrteVCRbIs5Sk2LOCZ06JB90OikG6gW32qsLbvWCW4FUFXede3-xWKeA9t_UX75V8OkswPro0WNS2XisoK1PaIqy0f_H4g_ALpZ2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2083724521</pqid></control><display><type>article</type><title>Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wong, Chun Y. ; Al-Salami, Hani ; Dass, Crispin R.</creator><creatorcontrib>Wong, Chun Y. ; Al-Salami, Hani ; Dass, Crispin R.</creatorcontrib><description>[Display omitted]
Diabetes is a chronic medical condition, which is characterised by high blood sugar level. Exogenous insulin is commonly administered subcutaneously for the management of diabetes. However, daily injections of insulin could result in poor patient compliance and various side-effects. Although oral administration offers benefits, insulin is vulnerable to enzymatic degradation, chemical instability and poor gastrointestinal absorption. There is an absence of reviews on insulin-loaded liposomal drug carriers, despite that fact that liposomes have gained considerable attention recently for oral delivery of insulin. They demonstrate favourable characteristics, such as versatility, biocompatibility, protective effect against enzymatic degradation, and cell-specific targeting. In this review, we will explore the status quo for oral delivery of insulin-loaded liposomal formulations, followed by discussing the state of art of these vesicles. This review will provide a detailed overview on insulin-loaded conventional liposomes, and 7 types of current novel formulations. Lastly, the future direction for oral bioavailability enhancement and development of such nanoscale drug delivery systems will be discussed. Further optimisation in the drug entrapment efficiency and gastrointestinal absorption will be required to develop a clinically successful oral liposome-insulin formulation.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2018.07.041</identifier><identifier>PMID: 30071309</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Oral ; Animals ; Biological Availability ; Cell-specific targeting ; Diabetes ; Diabetes Mellitus - drug therapy ; Drug Carriers - chemistry ; Drug Delivery Systems ; Humans ; Hypoglycemic Agents - administration & dosage ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - pharmacokinetics ; Insulin ; Insulin - administration & dosage ; Insulin - adverse effects ; Insulin - pharmacokinetics ; Liposome ; Liposomes ; Oral ; Surface coating</subject><ispartof>International journal of pharmaceutics, 2018-10, Vol.549 (1-2), p.201-217</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-1987f9f5db0d5526423d1d73f24740e1380dcba15b1f570aab08d3ccd2ebf6703</citedby><cites>FETCH-LOGICAL-c365t-1987f9f5db0d5526423d1d73f24740e1380dcba15b1f570aab08d3ccd2ebf6703</cites><orcidid>0000-0003-0049-6969</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0378517318305167$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30071309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wong, Chun Y.</creatorcontrib><creatorcontrib>Al-Salami, Hani</creatorcontrib><creatorcontrib>Dass, Crispin R.</creatorcontrib><title>Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted]
Diabetes is a chronic medical condition, which is characterised by high blood sugar level. Exogenous insulin is commonly administered subcutaneously for the management of diabetes. However, daily injections of insulin could result in poor patient compliance and various side-effects. Although oral administration offers benefits, insulin is vulnerable to enzymatic degradation, chemical instability and poor gastrointestinal absorption. There is an absence of reviews on insulin-loaded liposomal drug carriers, despite that fact that liposomes have gained considerable attention recently for oral delivery of insulin. They demonstrate favourable characteristics, such as versatility, biocompatibility, protective effect against enzymatic degradation, and cell-specific targeting. In this review, we will explore the status quo for oral delivery of insulin-loaded liposomal formulations, followed by discussing the state of art of these vesicles. This review will provide a detailed overview on insulin-loaded conventional liposomes, and 7 types of current novel formulations. Lastly, the future direction for oral bioavailability enhancement and development of such nanoscale drug delivery systems will be discussed. Further optimisation in the drug entrapment efficiency and gastrointestinal absorption will be required to develop a clinically successful oral liposome-insulin formulation.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Biological Availability</subject><subject>Cell-specific targeting</subject><subject>Diabetes</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Delivery Systems</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - pharmacokinetics</subject><subject>Insulin</subject><subject>Insulin - administration & dosage</subject><subject>Insulin - adverse effects</subject><subject>Insulin - pharmacokinetics</subject><subject>Liposome</subject><subject>Liposomes</subject><subject>Oral</subject><subject>Surface coating</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFuFDEMhqOKim4XHgGUI5cZnMlkMntCqCpQqRJSBecokzglq8lkSTIr7duTaheunGzZv_3bHyHvGLQM2PBx3_r94ZdOoe2AjS3IFnp2RTZslLzhvRxekQ1wOTaCSX5DbnPeA8DQMf6a3HAAyTjsNiQ9ocGlUG2PejEYap6pX2hMeq7F4BefS9LFx1pztZPX2S_NHLVFS2d_iDmGKrVpfaYWZ3_EdKL5lAuGTF1M1Ho9YcFMA86zL2t-Q66dnjO-vcQt-fnl_sfdt-bx-9eHu8-PjeGDKA3bjdLtnLATWCG6oe-4ZVZy1_WyB2R8BGsmzcTEnJCg9QSj5cbYDic3SOBb8uG895Di7xVzUcFnU4_QC8Y1qw5GLrteVCRbIs5Sk2LOCZ06JB90OikG6gW32qsLbvWCW4FUFXede3-xWKeA9t_UX75V8OkswPro0WNS2XisoK1PaIqy0f_H4g_ALpZ2</recordid><startdate>20181005</startdate><enddate>20181005</enddate><creator>Wong, Chun Y.</creator><creator>Al-Salami, Hani</creator><creator>Dass, Crispin R.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0049-6969</orcidid></search><sort><creationdate>20181005</creationdate><title>Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus</title><author>Wong, Chun Y. ; Al-Salami, Hani ; Dass, Crispin R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-1987f9f5db0d5526423d1d73f24740e1380dcba15b1f570aab08d3ccd2ebf6703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Biological Availability</topic><topic>Cell-specific targeting</topic><topic>Diabetes</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Delivery Systems</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - pharmacokinetics</topic><topic>Insulin</topic><topic>Insulin - administration & dosage</topic><topic>Insulin - adverse effects</topic><topic>Insulin - pharmacokinetics</topic><topic>Liposome</topic><topic>Liposomes</topic><topic>Oral</topic><topic>Surface coating</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wong, Chun Y.</creatorcontrib><creatorcontrib>Al-Salami, Hani</creatorcontrib><creatorcontrib>Dass, Crispin R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wong, Chun Y.</au><au>Al-Salami, Hani</au><au>Dass, Crispin R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2018-10-05</date><risdate>2018</risdate><volume>549</volume><issue>1-2</issue><spage>201</spage><epage>217</epage><pages>201-217</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted]
Diabetes is a chronic medical condition, which is characterised by high blood sugar level. Exogenous insulin is commonly administered subcutaneously for the management of diabetes. However, daily injections of insulin could result in poor patient compliance and various side-effects. Although oral administration offers benefits, insulin is vulnerable to enzymatic degradation, chemical instability and poor gastrointestinal absorption. There is an absence of reviews on insulin-loaded liposomal drug carriers, despite that fact that liposomes have gained considerable attention recently for oral delivery of insulin. They demonstrate favourable characteristics, such as versatility, biocompatibility, protective effect against enzymatic degradation, and cell-specific targeting. In this review, we will explore the status quo for oral delivery of insulin-loaded liposomal formulations, followed by discussing the state of art of these vesicles. This review will provide a detailed overview on insulin-loaded conventional liposomes, and 7 types of current novel formulations. Lastly, the future direction for oral bioavailability enhancement and development of such nanoscale drug delivery systems will be discussed. Further optimisation in the drug entrapment efficiency and gastrointestinal absorption will be required to develop a clinically successful oral liposome-insulin formulation.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>30071309</pmid><doi>10.1016/j.ijpharm.2018.07.041</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-0049-6969</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-5173 |
ispartof | International journal of pharmaceutics, 2018-10, Vol.549 (1-2), p.201-217 |
issn | 0378-5173 1873-3476 |
language | eng |
recordid | cdi_proquest_miscellaneous_2083724521 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Administration, Oral Animals Biological Availability Cell-specific targeting Diabetes Diabetes Mellitus - drug therapy Drug Carriers - chemistry Drug Delivery Systems Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Hypoglycemic Agents - pharmacokinetics Insulin Insulin - administration & dosage Insulin - adverse effects Insulin - pharmacokinetics Liposome Liposomes Oral Surface coating |
title | Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T09%3A50%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20advancements%20in%20oral%20administration%20of%20insulin-loaded%20liposomal%20drug%20delivery%20systems%20for%20diabetes%20mellitus&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Wong,%20Chun%20Y.&rft.date=2018-10-05&rft.volume=549&rft.issue=1-2&rft.spage=201&rft.epage=217&rft.pages=201-217&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2018.07.041&rft_dat=%3Cproquest_cross%3E2083724521%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2083724521&rft_id=info:pmid/30071309&rft_els_id=S0378517318305167&rfr_iscdi=true |